share_log

Have Insiders Sold Modern Chinese Medicine Group Shares Recently?

Have Insiders Sold Modern Chinese Medicine Group Shares Recently?

內部人士最近是否出售了現代中藥集團的股票?
Simply Wall St ·  03/29 06:28

We wouldn't blame Modern Chinese Medicine Group Co., Ltd. (HKG:1643) shareholders if they were a little worried about the fact that Xinlei Sun, the Executive Chairman recently netted about HK$18m selling shares at an average price of HK$0.38. That's a big disposal, and it decreased their holding size by 11%, which is notable but not too bad.

如果現代中藥集團有限公司(HKG: 1643)股東對執行主席孫欣雷最近以0.38港元的平均價格淨賣出約1800萬港元的股票感到擔憂,我們就不會責怪他們。這是一筆巨額出售,它使他們的持股規模減少了11%,這值得注意,但還不錯。

The Last 12 Months Of Insider Transactions At Modern Chinese Medicine Group

現代中藥集團最近12個月的內幕交易

Notably, that recent sale by Xinlei Sun is the biggest insider sale of Modern Chinese Medicine Group shares that we've seen in the last year. So what is clear is that an insider saw fit to sell at around the current price of HK$0.37. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. In this case, the big sale took place at around the current price, so it's not too bad (but it's still not a positive).

值得注意的是,孫欣蕾最近的出售是我們去年對現代中藥集團股票的最大一次內幕出售。因此,顯而易見的是,一位內部人士認爲以當前0.37港元左右的價格賣出是合適的。儘管內幕拋售是負面的,但對我們來說,如果以較低的價格出售股票,則負面影響更大。在這種情況下,大甩賣是在當前價格左右進行的,因此還不錯(但仍然不是積極的)。

You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!

您可以在下面看到對過去 12 個月內幕交易(公司和個人)的直觀描述。通過點擊下面的圖表,你可以看到每筆內幕交易的確切細節!

insider-trading-volume
SEHK:1643 Insider Trading Volume March 28th 2024
SEHK: 1643 內幕交易量 2024 年 3 月 28 日

I will like Modern Chinese Medicine Group better if I see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

如果我看到一些重大的內幕收購,我會更喜歡現代中藥集團。在我們等待的同時,請查看這份免費清單,列出了最近有大量內幕收購的成長型公司。

Does Modern Chinese Medicine Group Boast High Insider Ownership?

現代中藥集團是否擁有較高的內部所有權?

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. It's great to see that Modern Chinese Medicine Group insiders own 75% of the company, worth about HK$167m. I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.

我喜歡看看內部人士在一家公司擁有多少股票,以幫助我了解他們與內部人士的看法。較高的內部所有權通常會使公司領導層更加關注股東的利益。很高興看到現代中藥集團內部人士擁有該公司75%的股份,價值約1.67億港元。我喜歡看到這種程度的內部所有權,因爲它增加了管理層考慮股東最大利益的機會。

So What Does This Data Suggest About Modern Chinese Medicine Group Insiders?

那麼,這些數據對現代中藥集團內部人士有何啓示呢?

An insider sold stock recently, but they haven't been buying. And there weren't any purchases to give us comfort, over the last year. It is good to see high insider ownership, but the insider selling leaves us cautious. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. Case in point: We've spotted 3 warning signs for Modern Chinese Medicine Group you should be aware of.

一位內部人士最近出售了股票,但他們一直沒有買入。在過去的一年裏,沒有任何能讓我們感到安慰的購買。看到較高的內部所有權是件好事,但內幕拋售使我們持謹慎態度。因此,雖然了解內部人士在買入或賣出方面的所作所爲很有幫助,但了解特定公司面臨的風險也很有幫助。一個很好的例子:我們發現了現代中醫集團的3個警告信號,你應該注意。

But note: Modern Chinese Medicine Group may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

但請注意:現代中藥集團可能不是最值得買入的股票。因此,來看看這份投資回報率高、負債率低的有趣公司的免費清單。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

就本文而言,內部人士是指向相關監管機構報告其交易的個人。我們目前只考慮公開市場交易和私下處置的直接利益,不包括衍生品交易或間接權益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論